LANNETT CO INC
LANNETT CO INC (LCI): 25 pipeline candidates · ~43 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
43.4 months
D/E -1.81 · 0% dilution
Lead: Approved
25 candidates
N/A
N/A
A transparent, data-derived signal for LANNETT CO INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$51.5M
Quarterly Burn
$7.9M
Runway
43.4 mo
Revenue
$80.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (25 candidates)
| Drug | Phase |
|---|---|
| aripiprazole | Approved |
| atorvastatin | Approved |
| biosimilar insulin aspart | Preclinical |
| biosimilar insulin glargine | Preclinical |
| buprenorphine | Approved |
| butalbital | Approved |
| cetirizine | Approved |
| danazol | Approved |
| dextroamp saccharate | Approved |
| esomeprazole magnesium | Approved |
Showing 10 of 25 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in LANNETT CO INC's pipeline?
LANNETT CO INC (LCI) has 25 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is LANNETT CO INC's lead drug candidate?
LANNETT CO INC's most advanced tracked candidate is aripiprazole (Approved).
What is LANNETT CO INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, LANNETT CO INC has approximately 43.4 months of cash runway.
Who is the CEO of LANNETT CO INC?
Strategy The Board is the chief executive officer of LANNETT CO INC (LCI).
Get the full picture on LANNETT CO INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.